Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Imunon ( (IMNN) ) has issued an update.
On February 18, 2025, IMUNON appointed Dr. Douglas Faller as Chief Medical Officer to lead the company’s clinical strategy, including advancing its lead program IMNN-001 into a Phase 3 trial for advanced ovarian cancer. Dr. Faller brings over 30 years of experience in oncology and immunology, and his appointment is expected to bolster IMUNON’s efforts in progressing its pipeline of non-viral DNA-based immunotherapies, leveraging his expertise to drive clinical programs and potential commercialization.
More about Imunon
IMUNON is a clinical-stage biotechnology company focused on developing innovative treatments that utilize the body’s natural mechanisms to provide safe, effective, and long-lasting responses across a range of human diseases. The company is advancing its non-viral DNA technology through two main modalities: TheraPlas® for gene-based delivery of cytokines to treat solid tumors, and PlaCCine® for gene delivery of viral antigens. The lead program, IMNN-001, is a DNA-based immunotherapy aimed at treating advanced ovarian cancer, and the company is also conducting a study on a COVID-19 booster vaccine.
YTD Price Performance: -14.48%
Average Trading Volume: 260,348
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $13.02M
For an in-depth examination of IMNN stock, go to TipRanks’ Stock Analysis page.
